| Project/Area Number |
16K20381
|
|---|
| Research Category |
Grant-in-Aid for Young Scientists (B)
|
| Allocation Type | Multi-year Fund |
|---|
| Research Field |
Emergency medicine
|
|---|
| Research Institution | Gifu University |
|---|
Principal Investigator |
Suzuki Kodai 岐阜大学, 医学部附属病院, 助教 (80724583)
|
|---|
| Project Period (FY) |
2016-04-01 – 2018-03-31
|
| Project Status |
Completed (Fiscal Year 2017)
|
| Budget Amount *help |
¥3,770,000 (Direct Cost: ¥2,900,000、Indirect Cost: ¥870,000)
Fiscal Year 2017: ¥1,820,000 (Direct Cost: ¥1,400,000、Indirect Cost: ¥420,000)
Fiscal Year 2016: ¥1,950,000 (Direct Cost: ¥1,500,000、Indirect Cost: ¥450,000)
|
|---|
| Keywords | 敗血症 / 多臓器不全 / リコンビナントトロンボモジュリン / 血管内皮傷害 / 抗炎症 / リコンビナントロンボモジュリン |
|---|
| Outline of Final Research Achievements |
Multiple organ failure often occurs in sepsis via vascular endothelial injuries. It was recently reported that recombinant thrombomodulin (rTM) had anti-inflammatory and anticoagulant effects in sepsis. As a result, rTM-treated mice were significantly decreased mortality and each organ failures including heart, lung, liver and kidney compared with LPS-treated mice. In septic mice, endothelial wall became destroyed and endothelial glycocalyx was peeled away. On the other hands, rTM therapy attenuated endothelial injuries and endothelial glycocalyx injuries. These results demonstrated that rTM attenuates LPS-induced sepsis caused microvascular injuries and increases survival rate.
|
